SK2862004A3 - Amlodipine bezylate tablets with improved stability - Google Patents
Amlodipine bezylate tablets with improved stability Download PDFInfo
- Publication number
- SK2862004A3 SK2862004A3 SK286-2004A SK2862004A SK2862004A3 SK 2862004 A3 SK2862004 A3 SK 2862004A3 SK 2862004 A SK2862004 A SK 2862004A SK 2862004 A3 SK2862004 A3 SK 2862004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- tablets
- amlodipine
- active ingredient
- weight
- max
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 42
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 22
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 22
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 22
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 22
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 24
- 229960004005 amlodipine besylate Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 21
- 239000007884 disintegrant Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000008119 colloidal silica Substances 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract description 3
- 230000009965 odorless effect Effects 0.000 description 18
- 238000011109 contamination Methods 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 229940032147 starch Drugs 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 238000007907 direct compression Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- -1 2 - [(2-Aminoethoxy) methyl] -4- (2-chlorophenyl) -1,4-dihydro-6-methyl-3-ethyl-3,5-pyridinedicarboxylic acid 5-methyl ester Chemical compound 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920003110 Primojel Polymers 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000005429 MCC/DCP excipient Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105345A HU226642B1 (en) | 2001-12-17 | 2001-12-17 | Amlodipine bezylate tablets having extended stability and process for producing the same |
| PCT/HU2002/000145 WO2003051364A1 (en) | 2001-12-17 | 2002-12-17 | Amlopidine bezylate tablets with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK2862004A3 true SK2862004A3 (en) | 2004-11-03 |
Family
ID=90000366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK286-2004A SK2862004A3 (en) | 2001-12-17 | 2002-12-17 | Amlodipine bezylate tablets with improved stability |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1458384B1 (es) |
| AT (1) | ATE333877T1 (es) |
| AU (1) | AU2002353242A1 (es) |
| BG (1) | BG108807A (es) |
| CZ (1) | CZ2004791A3 (es) |
| DE (1) | DE60213464T2 (es) |
| EA (1) | EA006826B1 (es) |
| ES (1) | ES2269787T3 (es) |
| HR (1) | HRP20040582B1 (es) |
| HU (1) | HU226642B1 (es) |
| LT (1) | LT5241B (es) |
| LV (1) | LV13243B (es) |
| PL (1) | PL370420A1 (es) |
| RS (1) | RS54304A (es) |
| SK (1) | SK2862004A3 (es) |
| UA (1) | UA74968C2 (es) |
| WO (1) | WO2003051364A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| JP4954961B2 (ja) * | 2008-10-06 | 2012-06-20 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| JP5689052B2 (ja) * | 2011-12-26 | 2015-03-25 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| CN107441495A (zh) | 2012-02-17 | 2017-12-08 | 埃吉斯药物私人有限公司 | 稳定性提高的药物制剂 |
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| DE19857716A1 (de) * | 1998-12-15 | 2000-06-21 | Bayer Ag | Neue feste Formulierung von Metrifonat |
| WO2003032954A1 (en) * | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
-
2001
- 2001-12-17 HU HU0105345A patent/HU226642B1/hu unknown
-
2002
- 2002-12-17 CZ CZ2004791A patent/CZ2004791A3/cs unknown
- 2002-12-17 RS YU54304A patent/RS54304A/sr unknown
- 2002-12-17 EA EA200400801A patent/EA006826B1/ru not_active IP Right Cessation
- 2002-12-17 UA UA20040705877A patent/UA74968C2/uk unknown
- 2002-12-17 PL PL02370420A patent/PL370420A1/xx not_active IP Right Cessation
- 2002-12-17 AT AT02788262T patent/ATE333877T1/de not_active IP Right Cessation
- 2002-12-17 AU AU2002353242A patent/AU2002353242A1/en not_active Abandoned
- 2002-12-17 DE DE60213464T patent/DE60213464T2/de not_active Expired - Fee Related
- 2002-12-17 WO PCT/HU2002/000145 patent/WO2003051364A1/en active IP Right Grant
- 2002-12-17 EP EP02788262A patent/EP1458384B1/en not_active Expired - Lifetime
- 2002-12-17 SK SK286-2004A patent/SK2862004A3/sk unknown
- 2002-12-17 ES ES02788262T patent/ES2269787T3/es not_active Expired - Lifetime
-
2004
- 2004-06-23 HR HR20040582A patent/HRP20040582B1/xx not_active IP Right Cessation
- 2004-07-07 LT LT2004062A patent/LT5241B/lt not_active IP Right Cessation
- 2004-07-16 BG BG108807A patent/BG108807A/xx unknown
- 2004-07-16 LV LVP-04-82A patent/LV13243B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0105345A2 (hu) | 2003-12-29 |
| PL370420A1 (en) | 2005-05-30 |
| HRP20040582B1 (en) | 2007-08-31 |
| EA200400801A1 (ru) | 2004-12-30 |
| EA006826B1 (ru) | 2006-04-28 |
| HU226642B1 (en) | 2009-05-28 |
| ES2269787T3 (es) | 2007-04-01 |
| AU2002353242A1 (en) | 2003-06-30 |
| WO2003051364A1 (en) | 2003-06-26 |
| CZ2004791A3 (cs) | 2004-10-13 |
| LT2004062A (en) | 2005-02-25 |
| DE60213464D1 (de) | 2006-09-07 |
| RS54304A (en) | 2006-12-15 |
| BG108807A (en) | 2005-03-31 |
| EP1458384A1 (en) | 2004-09-22 |
| ATE333877T1 (de) | 2006-08-15 |
| LT5241B (lt) | 2005-07-25 |
| DE60213464T2 (de) | 2007-03-01 |
| HRP20040582A2 (en) | 2005-02-28 |
| UA74968C2 (en) | 2006-02-15 |
| EP1458384B1 (en) | 2006-07-26 |
| LV13243B (en) | 2005-05-20 |
| HUP0105345D0 (en) | 2002-02-28 |
| HUP0105345A3 (en) | 2007-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2311903C2 (ru) | Таблетки тамзулосина | |
| US20090226510A1 (en) | Pharmaceutical compositions of atorvastatin | |
| US20090196932A1 (en) | Pharmaceutical compositions of atorvastatin | |
| IL162451A (en) | 5ht4 partial agonist pharmaceutical compositions | |
| SK18062002A3 (sk) | Pevné orálne farmaceutické kompozície obsahujúce valsartan | |
| KR100760112B1 (ko) | 아토르바스타틴의 제약 조성물 | |
| SK2862004A3 (en) | Amlodipine bezylate tablets with improved stability | |
| CA2905423A1 (en) | Sovaprevir tablets | |
| EP2559431A1 (en) | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide | |
| EP2179725A1 (en) | Pharmaceutical composition comprising levetiracetam | |
| CA2450001A1 (en) | Stable pharmaceutical compositions containing pravastatin | |
| RU2674978C2 (ru) | Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида | |
| US20070281000A1 (en) | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof | |
| EP1864677A1 (en) | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | |
| WO2007142628A1 (en) | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof | |
| US20090269409A1 (en) | Pharmaceutical compositions comprising eszopiclone | |
| CA2343949A1 (en) | Benazepril hydrochloride tablet formulations | |
| Mohammed | Preparation Method and in Vitro Evaluation Method of Rosuvastatin Porous Tablets | |
| Patel et al. | Design, Development and Characterization of Immediate Release Tablet of Pioglitazone | |
| EA035891B1 (ru) | Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы | |
| AU2005200815A1 (en) | Solid valsartan pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Suspended procedure due to non-payment of fee |